

Claims

1. Use of a therapeutic gestagen for the production of a pharmaceutical agent for the treatment of premenstrual dysphoric disorder (PMDD).

2. Use of drospirenone, cyproterone acetate, dienogest according to claim 1.

3. Use according to claim 1, together with an estrogen.

4. Use according to claim 3, together with a synthetic estrogen.

5. Use according to claim 4, together with ethinylestradiol.

6. Use according to claim 3, together with an estrogen sulfamate.

7. Use according to claim 3, together with a natural estrogen.

8. Use according to claim 7, together with estradiol, estradiol valerate or another estradiol ester.

9. Use according to claim 1, only during the luteal phase of the female menstrual cycle.

10. Use according to claim 9 from day 10 to 28 of the menstrual cycle.

11. Use of drospirenone according to claim 1 in an amount of 0.5 mg to less than 5 mg daily.

12. Use of ethinylestradiol according to claim 5 in an amount of 0.010 to 0.05 mg daily.

13. Use of estradiol according to claim 8 in an amount of 1.0 g to 3.0 mg daily.

add A2